17.4 C
New York
Tuesday, June 9, 2026

Tag: vector

Fangzhou Showcases AI-Powered Chronic Disease Management Solution With Tencent Health at Tencent Cloud Conference

Fangzhou showcased its “AI + Chronic Disease Services” digital solution developed in collaboration with Tencent Health.

Visionary Advances on Multiple Fronts at Pt. Leamington: Phase 2 Drilling Permits Submitted; Prospecting Permits Filed for ~30,000 Ha Regional Land Package; Field Personnel...

HighlightsExploration Permit Applications filed for:Phase 2 Diamond Drilling at the Pt. Leamington VMS Deposit targeting deposit resource upgrade / expansion of the emerging Kraken...

Visionary Advances on Multiple Fronts at Pt. Leamington: Phase 2 Drilling Permits Submitted; Prospecting Permits Filed for ~30,000 Ha Regional Land Package; Field Personnel...

HighlightsExploration Permit Applications filed for:Phase 2 Diamond Drilling at the Pt. Leamington VMS Deposit targeting deposit resource upgrade / expansion of the emerging Kraken...

Orion Innovation and Amrita University Launch Applied GenAI Elective Program to Prepare Students for AI-Driven Careers

Industry-academia collaboration brings hands-on AI learning and real-world technology exposure to students across three campusesCOIMBATORE, India, June 4, 2026 /PRNewswire/ -- Orion Innovation ("Orion"), a...

NetFoundry Launches Enterprise-Class MCP and LLM Gateways, Bringing Zero Trust to AI Deployments

Identity-First Reachability™ eliminates the attack surface that AI agents, MCP servers, and LLMs create — addressing the #1 breach vector in enterprise security todayCHARLOTTE,...

Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy

MEQUON, Wis., June 2, 2026 /PRNewswire/ -- Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced that the Board of Directors...

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 12, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 58,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...

Cyberway and Dify Join Forces to Build Comprehensive Enterprise-Level AI Agents

GUANGZHOU, China, Aug. 14, 2025 /PRNewswire/ -- AI is reshaping the business world at an unprecedented pace. From early theoretical exploration to the explosive...

Striim Announces 5.2 – Major Release adds new AI Agents for Predictive Analytics and Vector generation for building novel Gen AI Enterprise Applications with...

PALO ALTO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) --  With fast emerging requirements for AI everywhere - Enterprises face new challenges in modernizing their core infrastructure, systems, and applications to adopt an AI-centric future. With an ever-expanding multi-cloud data estate, enterprises are grappling with brittle data pipelines, ETL based batch lag, lack of automated agents, and siloed data architectures that are complex to integrate.

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene’s Platform Technology

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development...

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsVector